Sunday recap @RheumNow Very interesting abstracts: https://t.co/BX8bDSX1M3 1- Fecal calprotectin in SpA population. 2-SLE; high or low steroids? Rapid or slow taper? 3-Molecular biomarkers for PAH in SLE. 4-Repeating imaging in ? Chronic back pain? And others …….

AS pts on UPA for 52 wks who were active or healthy weight/underweight at BL generally experienced greater decreases from BL in ASDAS-CRP and BASDAI vs pts who were inactive or overweight/obese. #ACR23 Abs #0540 https://t.co/OfgbmYUoAu @rheumno https://t.co/liptgbK2hJ

TNF AND IL17 was equally effective in Axial SpA! #ACR23 #Reviewcourse https://t.co/oofQkvsJ3f

Takeaways from #ACR23 #ReviewCourse session on SpA Update: Radiographic and Non-Radiographic AS - Dr. Alexis Ogdie 1. Workup of inflammatory back pain: History, exam, CRP, HLA-B27, SI joint films, MRI pelvis (STIR images, no need for contrast). Response to NSAIDs not actually… https://t.co/M0W6UNsPxF https://t.co/7k3xl1RXZz

ABS0524: ⭐️Benefit of Certolizumab (CZP) over standard non-biologic tx in reducing acute anterior uveitis (AAU) flares among high risk pts w/ axSpA ➡️active dz, HLAB27+, 2 or more AAU flares ⭐️CZP reduced AAU flare rate by 87% #ACR23 @RheumNow #ACRBest https://t.co/rW0N18agMO

ABS0538: ⭐️Characteristics of difficult-to-treat (D2T) axSpA pts: ➡️HLAB27(-) ➡️smokers ➡️shorter symptom duration ➡️more enthesitis ➡️IBD ➡️concomitant NSAID use ➡️Co-morbidities (HTN, HLD, fibro, depress/anxiety) #ACR23 @RheumNow https://t.co/TqEVBeaJpb

Yield of repeated assessments of SpA features in patients with CBP suspected of axSpA was modest for the increase of new definite axSpA diagnosis at 2y. Sacroilitis on MRI, good response to NSAIDs at BL most predictive of axSpA, ML Marques #ACR23 @RheumNow https://t.co/LQ5llML11M https://t.co/PYcCDypI7c

Utility of repeating assessments in chronic back pain pts suspected of early axSpA? 2 year study found a modest increase in new axSpA diagnosis after 2 years Yield of repeating MRI is low but can be considered in B27+ males @RheumNow #ACR23 Abs#0845 https://t.co/TgSEztUkTm

DRESS-PS study LTE. 12 month observational extension. 114 patients PsA/AxSpA. Essentially patients TNFi tapered or not in T2T fashion. TNFi dose remained lower in tapering group but it is consistently creeping back up. Abstr#0775 @RheumNow #ACR23 https://t.co/aYoOl6Ccin https://t.co/BtMR95lIfs

Abs#518 @RheumNow #ACR23 Deodhar: TOFA in AS, by b/l CRP levels 30% nml CRP (<5 mg/L) v 70% Elevated At wk 12, TOFA >> PBO regardless of b/l CRP Difference in response: greater in pts w elevated CRP Safety rates: elev. CRP c/w PBO, but nml CRP had trend of high AEs for tofa v PBO https://t.co/b9NRNkU8ub